TaKaRa Group Report

Overview

The report describes fiscal 2021 performance during the COVID-19 pandemic, with consolidated net sales of ¥278,443 million and record operating income of ¥21,595 million. It highlights Takara Bio's PCR testing system, molecular epidemiology research and vaccine-development manufacturing cooperation. The report also presents the Takara Group Sustainability Vision, including a consolidated net-zero CO2 target for FY2050.

Document

Report type: Integrated Report
Class: Embedded
Scope: Full report
Fiscal year: 2020-2021
Period: 1 April 2020 – 31 March 2021
Language: English
Pages
File size
Restatement: Disclosed

Standards

GRI
SASB
TCFD
ISSB
ESRS
Integrated Reporting Framework
GHG Protocol
EU Taxonomy
CDP
Other

Materiality

Assessment
Basis
Matrix

Assurance

Statement included

Services

Turn sustainability reports into a dataset built for your research.

From bulk PDFs to structured indicators and machine-readable documents.

View services